← Back to Methodology
RQS Scoring Log

Dihexa

Nootropics & Neuroprotection· Animal / In Vitro· Scored May 2026· View compound profile →
30 /100
Weak Evidence
7 dimensions · 100 points total · Methodology by PeptideClear
Dimension Breakdown
DimensionScoring NotesScore
Study Design
Mouse models only for cognitive enhancement and neurogenesis. No human clinical trials published. In vitro cell culture supplementary. Animal/in vitro only.
 5 / 25
Sample Size
No human participants.
 0 / 20
Replication
Primarily Joseph Harding/Don Bhargava research group (Washington State University). Limited independent replication by other groups.
 10 / 20
Journal Impact Factor
Published in Journal of Pharmacology and Experimental Therapeutics (IF ~4.5) and Neuropsychopharmacology (IF ~7). Reasonable journals for preclinical neuroscience.
 8 / 15
Funding Independence
NIH and academic (Washington State University) funded. Independent from commercial interests.
 4 / 10
Population Diversity
Animal/in vitro. Not applicable.
 0 / 5
Researcher h-Index
Joseph Harding (WSU) has h-Index ~30+ in neuropeptide research. Capped at 5.
 3 / 5
Animal Only Note
This score reflects evidence in humans. Animal and in vitro evidence may be substantially stronger than the score suggests — this compound has not yet been studied in human trials.
Scored by the PeptideClear editorial team using publicly available literature. Sources: PubMed (study design, sample size, replication) · ScimagoJR (journal impact factor) · Google Scholar (researcher h-Index) · Primary papers (funding disclosure). Scores are reviewed as new research is published.